SLC5A2 and diabetes mellitus: This assumption is supported by a meta-analysis of two RCTs (DAPA-HF for dapagliflozin and EMPEROR-Reduced for empagliflozin) in patients with HF, which showed that SGLT2-i users with and without diabetes have a similar reduction in the risk of a composite endpoint consisting of hospitalization for HF (HHF) and CV death (Zannad et al., 2020).